1310704-15-4

Basic information

• Product Name: ethyl 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
• Synonyms: ethyl 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
• CAS NO: 1310704-15-4
• Molecular Formula: C₁₉H₂₉ClN₂O₂Si
• Molecular Weight: 380.98426
• Mol File: 1310704-15-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate(1310704-15-4)
• EPA Substance Registry System: ethyl 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate(1310704-15-4)

Safety Data

• Hazardous Substances Data: 1310704-15-4(Hazardous Substances Data)

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 651744-48-8 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 
• 13154-24-0 triisopropylsilyl chloride 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 1310731-53-3 C₂₃H₂₇N₃O₄S 
• 1310731-55-5 C₂₁H₂₃N₃O₃S 
• 1310731-56-6 C₂₅H₂₉N₃O₄S 
• 1310731-57-7 C₂₅H₃₁N₃O₄S 
• 1310731-58-8 C₂₃H₂₇N₃O₂S 
• 1310728-84-7 1-cyclohexyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h][1,6]naphthyridine 
• 1310731-54-4 C₂₁H₂₅N₃O₃S 
• 920966-03-6 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 

Relevant articles and documents

JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF

A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-related diseases, specifically, uses in preventing or treating inflammatory diseases related to protein tyrosine kinase.

NOVEL COMPOUNDS

The invention relates to compound of the formula (I) or its salt, wherein -R1, -R2, -R3, -R4, -R5, -M-, -X- and -Y= are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.